Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ifosfamide-induced encephalopathy.

Ana M Gonzalez-Angulo1, Jennifer A Orzano, Enrique Davila

  • 1Department of Medicine, Mount Sinai Medical Center, Miami Beach, Fla 33140, USA.

Southern Medical Journal
|November 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.

Cancer letters·2025
Same author

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.

European journal of cancer (Oxford, England : 1990)·2019
Same author

Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer.

Molecular cancer therapeutics·2018
Same author

Impact of clinical trial on survival outcomes.

Breast cancer research and treatment·2016
Same author

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2016

This case study shows a patient with bladder cancer who experienced reversible encephalopathy after ifosfamide/mesna chemotherapy. Retreatment with the same chemotherapy did not cause further central nervous system effects, suggesting this adverse event may not always recur.

Area of Science:

  • Oncology
  • Neuro-oncology
  • Pharmacology

Background:

  • Metastatic transitional cell carcinoma of the bladder is a significant clinical challenge.
  • Ifosfamide/mesna is a chemotherapy regimen used for bladder cancer.
  • Chemotherapy-induced encephalopathy is a known, though infrequent, adverse effect.

Observation:

  • A 46-year-old male patient with metastatic bladder cancer developed reversible encephalopathy after the first cycle of ifosfamide/mesna.
  • The patient achieved a significant clinical response with tumor size reduction.
  • Subsequent identical chemotherapy administration did not result in recurrence of central nervous system adverse effects.

Findings:

  • This case suggests that ifosfamide/mesna-induced encephalopathy may not be a contraindication for retreatment.

Related Experiment Videos

  • Successful retreatment without neurological toxicity was observed in this patient.
  • Limited data exists on retreatment protocols following chemotherapy-induced neurotoxicity.

    • Implications:

    • This finding could inform clinical decision-making regarding retreatment strategies for patients experiencing chemotherapy-induced encephalopathy.
    • Further research is warranted to understand the mechanisms and predictability of ifosfamide/mesna neurotoxicity.
    • This case highlights the potential for successful continuation of effective chemotherapy despite prior adverse events.